Crispr Therapeutics AG (CRSP) Receives a Buy from Chardan Capital
In a report released yesterday, Geulah Livshits from Chardan Capital maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research ...
Why CRISPR Therapeutics Stock Was a Massive Winner on Wednesday
On Hump Day, investors piled into CRISPR Therapeutics (NASDAQ: CRSP) stock, sending its price more than 9% higher at the ...
Crispr Therapeutics price target raised to $86 from $85 at BofA
BofA analyst Alec Stranahan raised the firm’s price target on Crispr Therapeutics (CRSP) to $86 from $85 and keeps a Buy rating on the shares. With sufficient cash to support “years of development in ...
Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday
Gilead Sciences reported quarterly earnings of $1.90 per share which beat the analyst consensus estimate of $1.70. Quarterly revenue came in at $7.56 billion which beat the analyst consensus estimate ...
CRISPR upgraded to hold by TD Cowen on limited downside
TD Cowen has upgraded CRISPR Therapeutics (CRSP) to hold from sell, stating it now sees less downside to the stock. Read more ...
CRISPR stock rating raised to hold by TD Cowen, target steady
CRISPR Therapeutics (NASDAQ:CRSP) received an upgrade in its stock rating by analysts at TD Cowen, changing from Sell to Hold, while maintaining a price target of $35.00. The revision in the rating ...
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Crispr Therapeutics AG (CRSP), Jazz Pharmaceuticals (JAZZ) and PTC Therapeutics (PTCT)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Crispr Therapeutics AG (CRSP – Research Report), Jazz ...
CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...
Q1 EPS Forecast for CRISPR Therapeutics Decreased by Analyst
Zacks Research decreased their Q1 2025 EPS estimates for CRISPR Therapeutics in a report issued on Wednesday, February 5th. Zacks Research analyst R. Department now anticipates that the company will ...